ArticleClinical epigenetics2026
Genomic characterization of uterine adenomatoid tumors reveals recurrent alterations in KMT5A and KMT2C.
Article in Clinical epigenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUterine adenomatoid tumors (UATs) are rare benign mesothelial neoplasms with poorly characterized molecular features. Comprehensive genomic profiling of UATs remains limited.
methodsTargeted sequencing of 20 pathologically confirmed UATs was performed using a 641-gene panel. Immunohistochemical (IHC) analyses were conducted to assess protein expression patterns. Functional assays were performed in the Ishikawa endometrial carcinoma cell line to provide preliminary insight into the potential biological impact of KMT5A knockdown. Publicly available datasets (TCGA and cBioPortal) were analyzed to place these alterations into a broader molecular context across gynecologic malignancies.
resultsRecurrent mutations in KMT5A and KMT2C were identified in all cases (20/20, 100%), with consistent co-occurrence across the cohort. Additional alterations were observed in HLA-B (65%), HLA-A (50%), ROS1 (45%), TRAF7 (45%), SDHA (30%), and KMT2A (30%). IHC analysis demonstrated higher expression of TRAF7, γ-H2AX, CALB2, and Ki-67 in tumors with elevated KMT5A expression. KMT5A knockdown in Ishikawa cells reduced proliferative and migratory capacity. Comparative analyses indicated that KMT5A mutations are uncommon in gynecologic malignancies (< 3%), whereas KMT2C alterations are more broadly distributed.
conclusionsUATs exhibit a distinctive mutational profile characterized by recurrent KMT5A and KMT2C co-mutations. These findings provide a comprehensive molecular characterization of UATs and suggest that recurrent alterations in chromatin-regulatory genes may represent characteristic genomic features that warrant further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.